{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-014351","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.304489+00:00","generated_at":"2026-05-26T21:38:03.110726+00:00","sec_items":["8.01","2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Citius Oncology reports wider Q1 net loss of $6.7M; engaged Jefferies for strategic alternatives","bullets":["Net loss of $6.7M ($0.09/share) vs $4.7M ($0.07) in Q1 fiscal 2024.","G&A expenses rose to $3.3M from $1.5M on pre-commercial launch costs for LYMPHIR.","Engaged Jefferies as exclusive financial advisor to evaluate strategic alternatives; active discussions underway.","Received permanent J-code J9161 for LYMPHIR effective April 1, 2025; launch on track for H1 2025.","R&D expenses were $1.3M, up from $1.2M, supporting two investigator-initiated trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-014351","json":"https://secwatch.observer/filing/0001213900-25-014351.json","markdown":"https://secwatch.observer/filing/0001213900-25-014351.md","text":"https://secwatch.observer/filing/0001213900-25-014351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025014351/0001213900-25-014351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025014351/ea0231246-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:38:03.110726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}